The global acute respiratory distress syndrome (ARDS) market refers to the collective economic landscape associated with diagnosing, treating, and preventing ARDS worldwide. ARDS is a severe lung condition characterized by the rapid onset of widespread lung inflammation, leading to respiratory failure. The market encompasses pharmaceuticals, medical devices, and therapeutic interventions addressing ARDS. As the demand for effective treatments intensifies, pharmaceutical companies and medical device manufacturers strive to develop innovative solutions, fostering competition and enhancing the overall outlook of the ARDS market worldwide.
Access Full Report @ https://www.databridgemarketresearch.com/fr/reports/global-acute-respiratory-distress-syndrome-ards-market
Data Bridge Market Research analyses that the Global Acute Respiratory Distress Syndrome (ARDS) Market, which was USD 1,29,655.84 million in 2022, is expected to reach USD 2,79,956.55 million by 2030, at a CAGR of 10.1% during the forecast period 2023 to 2030. The rising incidence of acute respiratory distress syndrome (ARDS) is a crucial market driver. As more individuals are affected by this life-threatening condition, a growing demand for innovative treatments and therapies propels market growth.
Key Findings of the Study
Aging population is expected to drive the market's growth rate
The elderly population's increased susceptibility to acute respiratory distress syndrome (ARDS) is significant in market expansion. Individuals often experience weakened lung function and reduced respiratory capacity with advancing age, making them more vulnerable to ARDS. As the global population ages, the prevalence of ARDS among older adults is increasing and creating a greater demand for medical interventions and treatments, thereby expanding the ARDS market to address the unique needs of this demographic.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Pure Silica Fiber, Polycrystalline Fiber, Polymer Optical), Fiber Type (Single-Mode Optical Fiber and Multimode Optical Fiber), Usage (Re-usable, Disposable), End User (Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Contract Research Organization (CRO), Diagnostic Laboratories), Application (Image Transmission, Laser Signal Delivery, Illumination, Laser soldering, Fiber Optic Confocal Scanning)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd (Switzerland), Bayer AG (Germany), Sun Pharmaceutical Industries Ltd (India), Novartis AG (Switzerland), Drägerwerk AG & Co. KGaA (Germany), Fisher & Paykel Healthcare Limited (New Zealand), LivaNova PLC (U.K.), Besmed Health Business Corp. (Taiwan), Armstrong Medical (U.K.), Pfizer Inc. (U.S.), WEINMANN Emergency Medical Technology GmbH + Co. KG (Germany), Terumo Medical Corporation (U.S.), Getinge AB. (Sweden), EUROSETS (Italy)
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
The global acute respiratory distress syndrome (ARDS) Market is segmented on the basis of cause, type, route of administration, end user, and distribution channel.
- On the basis of cause, the global acute respiratory distress syndrome (ARDS) Market is segmented into coronavirus disease 2019 (COVID-19), sepsis, inhalation of harmful substances, severe pneumonia, and others
- On the basis of type, the global acute respiratory distress syndrome (ARDS) Market is segmented into diagnosis, and treatment
- On the basis of route of administration, the global acute respiratory distress syndrome (ARDS) Market is segmented into oral, parenteral, and other
- On the basis of end user, the global acute respiratory distress syndrome (ARDS) Market is segmented into hospitals, specialty clinics, home healthcare, and others
- On the basis of distribution channel, the global acute respiratory distress syndrome (ARDS) Market is segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy, and others
Major Players
Data Bridge Market Research recognizes the following companies as the major global acute respiratory distress syndrome (ARDS) Market players in global acute respiratory distress syndrome (ARDS) Market are Besmed Health Business Corp. (Taiwan), Armstrong Medical (U.K.), Pfizer Inc. (U.S.), WEINMANN Emergency Medical Technology GmbH + Co. KG (Germany), Terumo Medical Corporation (U.S.), Getinge AB. (Sweden), EUROSETS (Italy)
Market Developments
- In April 2022, the FDA approved Direct Biologics for a groundbreaking Phase 3 clinical trial. This trial aims to evaluate the efficacy of the investigational EV Drug ExoFlow in treating acute respiratory distress syndrome (ARDS). This significant milestone paves the way for advanced research and potential therapeutic solutions to address a critical medical condition, offering hope for improved outcomes for ARDS patients
- In January 2022, Veru announced that its drug, Sabizabulin, received a fast-track designation from the FDA for treating hospitalized COVID-19 patients at high risk of developing acute respiratory distress syndrome (ARDS). This designation expedites the drug's development and regulatory process, recognizing its potential to address a critical need in managing severe COVID-19 cases and preventing the onset of ARDS in vulnerable patients
- In February 2021, Pfizer Inc. CentreOne introduced a campaign showcasing their extensive selection of complex API compounds and intermediates tailored for drug product developers and manufacturers. This strategic initiative aimed to bolster their presence in the U.S. market. By highlighting their diverse API offerings, Pfizer Inc. CentreOne aimed to provide enhanced support and solutions to pharmaceutical companies, contributing to their growth and success within the U.S. pharmaceutical landscape
- In January 2020, ResMed introduced the AirTouch N20 Foam CPAP Mask, featuring their first-ever nasal memory foam cushion. This innovation prioritized patient comfort and convenience as the cushion didn't require cleaning when replaced on schedule. The AirTouch N20 added to ResMed's range of user-friendly and comfortable masks. This product portfolio expansion allowed ResMed to offer enhanced solutions, catering to a broader spectrum of patient needs in the respiratory care market.
Regional Analysis
Geographically, the countries covered in the global acute respiratory distress syndrome (ARDS) Market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
As per Data Bridge Market Research analysis:
North America is the dominant region in the global acute respiratory distress syndrome (ARDS) Market during the forecast period 2023-2030
North America dominates the acute respiratory distress syndrome (ARDS) market due to recent technological strides and a wealth of advanced pharmacological options, that enhancing therapeutic efficacy. The region's robust healthcare infrastructure and focus on innovation have propelled it to the forefront of ARDS treatment. The availability of cutting-edge pharmaceutical molecules underscores North America's commitment to improving patient outcomes and signifies its dominance in advancing the therapeutic landscape for ARDS.
Asia-Pacific is estimated to be the fastest growing region in global acute respiratory distress syndrome (ARDS) Market during the forecast period 2023-2030
The Asia-Pacific region is expected to show substantial growth from 2023 to 2030, driven by a surge in biotechnology research and center activities. Increased investment and focus on biotechnological advancements contribute to the region's prominence in the forecast period, positioning it as a key player in the global market. The rise in research and development initiatives underscores Asia-Pacific's pivotal role in shaping the future landscape of biotechnology, fostering innovation, and driving economic expansion in the process.
For more detailed information about the global acute respiratory distress syndrome (ARDS) Market report, click here – https://www.databridgemarketresearch.com/fr/reports/global-acute-respiratory-distress-syndrome-ards-market
